Monoclonal Antibodies for COVID-19 in Children: Case Series Should be Just the Start

Zheyi Teoh; Zachary I Willis

doi:10.1093/jpids/piad006

Monoclonal Antibodies for COVID-19 in Children: Case Series Should be Just the Start

J Pediatric Infect Dis Soc. 2023 Apr 18;12(3):156-158. doi: 10.1093/jpids/piad006.

Authors

Zheyi Teoh¹, Zachary I Willis²

Affiliations

¹ Division of Infectious Diseases, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
² Division of Pediatric Infectious Diseases, Department of Pediatrics, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.

PMID: 36928718
DOI: 10.1093/jpids/piad006

Abstract

Two new articles describe the use and implementation of monoclonal antibodies to treat COVID-19 in children. While these studies provide valuable guidance for pediatric clinicians, more studies of monoclonal antibodies and other COVID-19 therapies in children are needed.

Keywords: COVID-19; SARS-CoV-2; monoclonal antibodies; pediatric.

© The Author(s) 2023. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Publication types

Editorial
Comment

MeSH terms

Antibodies, Monoclonal / therapeutic use
COVID-19*
Child
Humans
Retrospective Studies

Substances

Antibodies, Monoclonal